Endocrine Abstracts

Introduction: Type 2 diabetes is one of the main risk factors for severe COVID 19 infection. Inadequate glycemic control is related to high inflammation, hypercoagulability, and mortality in COVID-19 patients. Glucose lowering medications commonly used to treat diabetes mellitus (DM) might have effects on COVID 19 pathogenesis. Overall, evidence is conflicting as to which glucose-lowering drugs are associated with the most favourable outcomes in patients with COVID-19. The aim...

Introduction: IDegLira is the first fixed ratio combination of a basal insulin degludec and a glucagon-like peptide-receptor analogue liraglutide. These combination producereduction in glycated hemoglobin A1c (HbA1c) and help to mitigate the weight gain. The aim of this study was to evaluate relationship between change in glycemic parameters and body weight in patients who began therapy with IDegLira.Patients and Methods: Retrospective study included 86 ...